Related Articles
Clinical activity of crizotinib in lung adenocarcinoma harboring a <em>HLA_A</em>‑<em>ROS1</em> rearrangement: A case report
Efficacy and survival outcomes of alectinib vs. crizotinib in ALK‑positive NSCLC patients with CNS metastases: A retrospective study
ALK inhibitors and advanced non-small cell lung cancer (Review)
A real‑world study of treatment patterns and survival outcome in advanced anaplastic lymphoma kinase‑positive non‑small‑cell lung cancer
CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma